“The existing situation has exposed some structural weaknesses within the EU’s medicines supply chain and a higher dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides claimed. She recommended that offer chain troubles be resolved in an EU pharmaceutical method expected to